Updated: January 21, 2026
How to Save Money on Actemra in 2026: Coupons, Discounts, and Patient Assistance
Author
Peter Daggett

- What Does Actemra Actually Cost?
- Option 1: Actemra Co-pay Program (For Commercially Insured Patients)
- Option 2: Genentech Patient Foundation (For Uninsured or Low-Income Patients)
- Option 3: PAN Foundation Patient Assistance
- Option 4: Ask About a Biosimilar — Potential Insurance Savings
- Option 5: Medicare Patients — What Are Your Options?
- Tips for Maximizing Savings
Overview
Actemra (tocilizumab) costs thousands per month at list price. Learn about the co-pay card, Genentech Patient Foundation, biosimilar savings, and other ways to reduce your cost in 2026.
Is Actemra in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Actemra near you.
Actemra (tocilizumab) is one of the more expensive specialty biologics on the market. The monthly cost can range from roughly $2,300 to nearly $5,000 depending on your formulation and dosing frequency — well beyond what most patients can afford out-of-pocket. Fortunately, a range of assistance programs can significantly reduce or even eliminate your cost. Here's a complete breakdown.
What Does Actemra Actually Cost?
At retail list price, Actemra's costs break down as follows, according to Genentech:
- Actemra IV: approximately $2,308–$4,616 per month, depending on which dose you receive
- Actemra SC: approximately $2,478–$4,956 per month, depending on weekly vs. every-other-week dosing
These are list (retail) prices before insurance, manufacturer assistance, or any other discounts. Most patients with insurance or assistance programs pay far less — but knowing the starting price helps you understand why these programs matter so much.
Check live stock now.
Option 1: Actemra Co-pay Program (For Commercially Insured Patients)
If you have commercial (private) insurance, the Actemra Co-pay Program is your most powerful savings tool. Eligible commercially insured patients may pay as little as $0 per treatment with the program, with a maximum savings of $15,000 per calendar year.
How to enroll:
- Visit racopay.com to register online, or ask your doctor's office to help enroll you
- Call 1-855-722-6729 for assistance
- You must have a valid prescription and commercial (not government) insurance
Important: This program cannot be used with Medicare, Medicaid, or any other federal or state government health programs.
Option 2: Genentech Patient Foundation (For Uninsured or Low-Income Patients)
If you don't have insurance, or if your insurance doesn't cover Actemra and you have financial concerns, the Genentech Patient Foundation may provide Actemra at no cost. Eligibility is based on household size and income:
- Household income within specific income guidelines (contact the program for current thresholds — these are adjusted periodically)
- Out-of-pocket maximum exceeds 7.5% of your household income under your current health plan
How to apply: Both you and your doctor must complete forms (Patient Consent Form and Prescriber Foundation Form). Contact the Foundation at 1-888-941-3331 (Mon–Fri, 6AM–5PM PST), or visit genentech-access.com. Processing takes about 5 business days after both forms are received.
Option 3: PAN Foundation Patient Assistance
The Patient Access Network (PAN) Foundation provides co-pay assistance to underinsured patients. You must have insurance and a valid Actemra prescription to apply. Contact PAN Foundation at 1-866-316-7263 or visit panfoundation.org to check eligibility and apply. PAN programs open and close based on funding availability, so check their website for current status.
Option 4: Ask About a Biosimilar — Potential Insurance Savings
Tocilizumab biosimilars (Tofidence, Tyenne, Avtozma) may be covered at a lower cost-sharing tier than brand-name Actemra under your insurance plan. Many plans in 2026 have biosimilars as preferred drugs with lower copays. Ask your insurance company which tocilizumab product is on the preferred formulary tier, and ask your doctor if switching to that product makes clinical sense for you.
Option 5: Medicare Patients — What Are Your Options?
Manufacturer co-pay cards cannot be used with Medicare. However, Medicare patients have other options:
- Medicare Part D Out-of-Pocket Cap: As of 2026, Medicare Part D has a $2,100 annual out-of-pocket cap, which limits your total yearly cost for covered drugs.
- Genentech Patient Foundation: Medicare patients may qualify based on income and household size.
- Extra Help (Low Income Subsidy): Medicare's Extra Help program (also called the Low Income Subsidy) significantly reduces drug costs for eligible low-income Medicare beneficiaries.
Found
Rate
on average
Tips for Maximizing Savings
- Enroll in the co-pay program before your first dose — retroactive rebates are possible but not guaranteed
- Ask your specialty pharmacy about the $0 copay program at the time of dispensing — they can often apply it automatically
- Review your coverage every year during open enrollment — biosimilar cost-sharing may be lower than brand Actemra
Want to learn more about what Actemra is and how it works? See our guide: What Is Actemra? Uses, Dosage, and What You Need to Know in 2026. If you're having trouble finding it, medfinder can help locate Actemra at pharmacies near you.
Frequently Asked Questions
With the Genentech Actemra Co-pay Program, commercially insured patients may pay as little as $0 per treatment (up to $15,000/year savings). Without this program, your out-of-pocket cost depends on your plan's tier and cost-sharing structure — specialty biologics like Actemra are typically on a specialty tier with 20–33% coinsurance after deductible.
GoodRx can help with some specialty medications, but Actemra's distribution is highly controlled through authorized specialty pharmacies. For most patients, the Genentech Co-pay Program (for insured patients) or the Genentech Patient Foundation (for uninsured patients) will provide better savings than a discount card. GoodRx shows prices starting around $575.78 for smaller quantities, but your pharmacist and Genentech's programs are typically the best path.
Actemra IV is typically covered under Medicare Part B as a physician-administered drug. Actemra SC may be covered under Medicare Part D. As of 2026, Part D has a $2,100 annual out-of-pocket cap. Manufacturer co-pay cards cannot be used with Medicare, but the Genentech Patient Foundation and Extra Help (Low Income Subsidy) may be available.
Biosimilars like Tyenne and Avtozma are typically priced lower than brand Actemra, and many insurance plans place them on a preferred tier with lower cost-sharing. If your plan prefers a biosimilar, switching could reduce your copay or coinsurance. Ask your insurer and prescriber which tocilizumab product is most cost-effective for your specific plan.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Actemra also looked for:
More about Actemra
39,345 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





